Home/Pipeline/BREN02 / hEN1

BREN02 / hEN1

Amyotrophic Lateral Sclerosis (ALS)

Pre-clinicalActive

Key Facts

Indication

Amyotrophic Lateral Sclerosis (ALS)

Phase

Pre-clinical

Status

Active

Company

BrainEver

About BrainEver

BrainEver is a clinical-stage biotech pioneering a novel therapeutic class based on homeoproteins—neuron maintenance and rejuvenation factors—to treat neurodegenerative diseases. The company's lead program, BREN02 (hEN1 for ALS), is in late preclinical development, supported by a recent €33M Series B financing to initiate a European clinical trial. With a pipeline spanning ALS, Parkinson's, and retinal disorders, BrainEver aims to deliver disease-modifying treatments by targeting the underlying biology of neuronal survival and function.

View full company profile

Therapeutic Areas

Neurodegenerative Diseases Ophthalmology

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

Drug	Company	Phase	Status
NPT520-34	Neuropore Therapies	Pre-clinical/Phase 1	Partnered (Biogen), Active
NUZ-001	Neurizon Therapeutics	Phase 2/3 (Platform Trial)	Active
CNM-Au8	Clene	Phase 2/3	Active
Masitinib	AB Science	Phase 3	Active
Undisclosed Program	Zhimeng Biopharma	Clinical	Active
SLS-005	Seelos Therapeutics	Platform Trial	Active (HEALEY ALS Platform Trial – Regimen E)
PMN442	ProMIS Neurosciences	Preclinical	Active
nAV-101	nVector	Pre-clinical	Active
ALTA-808	Alteron Therapeutics	Preclinical	IND-enabling studies launching
GM6	Genervon Biopharmaceuticals	Phase 2	Active
Lou Gehrig’s disease	Genclis	Discovery	Active
Treg-directed therapy for ALS	Iltoo Pharma	Pre-clinical	Active